Zenas BioPharma to Present at the Guggenheim SMID Cap Biotech Conference
Zenas BioPharma (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company focused on immunology-based therapies, has announced its participation in the Guggenheim SMID Cap Biotech Conference. The company's management will engage in a fireside chat presentation scheduled for Wednesday, February 5, 2025, at 3:00 p.m. ET.
Interested parties can access both the live webcast and archived replay of the presentation through the 'Events and Presentations' section within the Investor & Media Relations area of the Zenas BioPharma website.
Zenas BioPharma (Nasdaq: ZBIO), un'azienda biofarmaceutica globale in fase clinica focalizzata sulle terapie basate sull'immunologia, ha annunciato la sua partecipazione alla Guggenheim SMID Cap Biotech Conference. Il management dell'azienda parteciperà a una presentazione in stile fireside chat programmata per mercoledì 5 febbraio 2025, alle 15:00 ET.
Le parti interessate possono accedere sia alla diretta streaming che alla registrazione archivio della presentazione attraverso la sezione 'Eventi e Presentazioni' nell'area Relazioni con Investitori e Media del sito web di Zenas BioPharma.
Zenas BioPharma (Nasdaq: ZBIO), una empresa biofarmacéutica global en etapa clínica centrada en terapias basadas en inmunología, ha anunciado su participación en la Guggenheim SMID Cap Biotech Conference. La dirección de la compañía participará en una presentación estilo fireside chat programada para miércoles 5 de febrero de 2025, a las 3:00 p.m. ET.
Las partes interesadas pueden acceder tanto a la transmisión en vivo como a la repetición archivada de la presentación a través de la sección 'Eventos y Presentaciones' en el área de Relaciones con Inversores y Medios del sitio web de Zenas BioPharma.
제나스 바이오파마 (Nasdaq: ZBIO)는 면역학 기반 치료에 집중하는 임상 단계의 글로벌 생명공학 회사로서 구겐하임 SMID 캡 바이오텍 회의에 참가한다고 발표했습니다. 회사 관리팀은 2025년 2월 5일 수요일, 오후 3시 ET에 예정된 파이어사이드 채팅 발표에 참여할 예정입니다.
관심 있는 당사자들은 제나스 바이오파마 웹사이트의 투자자 및 미디어 관계 영역 내 '이벤트 및 발표' 섹션을 통해 프레젠테이션의 라이브 웹캐스트와 아카이브 재생을 모두 액세스할 수 있습니다.
Zenas BioPharma (Nasdaq: ZBIO), une entreprise biopharmaceutique globale en phase clinique axée sur les thérapies basées sur l'immunologie, a annoncé sa participation à la Guggenheim SMID Cap Biotech Conference. La direction de l'entreprise participera à une présentation sous forme de fireside chat prévue pour mercredi 5 février 2025, à 15h00 ET.
Les parties intéressées peuvent accéder à la diffusion en direct ainsi qu'à la rediffusion archivée de la présentation via la section 'Événements et Présentations' dans la zone Relations Investisseurs et Médias du site web de Zenas BioPharma.
Zenas BioPharma (Nasdaq: ZBIO), ein klinisches globales biopharmazeutisches Unternehmen, das sich auf immunologisch basierte Therapien konzentriert, hat seine Teilnahme an der Guggenheim SMID Cap Biotech Conference angekündigt. Das Management des Unternehmens wird an einer Fireside-Chat-Präsentation teilnehmen, die für Mittwoch, den 5. Februar 2025, um 15:00 Uhr ET geplant ist.
Interessierte Parteien können sowohl die Live-Übertragung als auch die archivierte Wiederholung der Präsentation über den Bereich 'Veranstaltungen und Präsentationen' im Bereich Investor- und Medienbeziehungen der Website von Zenas BioPharma zugreifen.
- None.
- None.
WALTHAM, Mass., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies, today announced management’s fireside chat presentation at the Guggenheim SMID Cap Biotech Conference on Wednesday, February 5, 2025, at 3:00 p.m. ET.
A live webcast and archived replay of the Company’s presentation can be accessed under “Events and Presentations” in the Investor & Media Relations section of the Zenas BioPharma website.
About Zenas BioPharma, Inc.
Zenas is a clinical-stage global biopharmaceutical company committed to becoming a leader in the development and commercialization of transformative immunology-based therapies for patients in need. Our core business strategy combines our experienced leadership team with a disciplined product candidate acquisition approach to identify, acquire and develop product candidates globally that we believe can provide superior clinical benefits to patients living with autoimmune diseases. Zenas’ lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. We believe that obexelimab’s unique mechanism of action and self-administered, subcutaneous injection regimen may broadly and effectively address the pathogenic role of B cell lineage in chronic autoimmune disease. For more information about Zenas BioPharma, please visit www.zenasbio.com and follow us on LinkedIn.
The Zenas BioPharma word mark and logos are trademarks of Zenas BioPharma, Inc. or its affiliated companies.
Investor Contact:
Matthew Osborne
Investor Relations and Corporate Communications
Matt.osborne@zenasbio.com
Media Contact:
Argot Partners
FAQ
When is Zenas BioPharma (ZBIO) presenting at the Guggenheim SMID Cap Biotech Conference 2025?
How can investors watch Zenas BioPharma's (ZBIO) Guggenheim Conference presentation?
What type of presentation will ZBIO deliver at the Guggenheim SMID Cap Biotech Conference?
Where will the archived replay of ZBIO's Guggenheim Conference presentation be available?
